Skip to content
Clinical Trials – home
AustriaBack to Austria

Clinical trials in Ried Im Innkreis

123 clinical trials in Ried Im Innkreis, Austria. Every trial is listed in the EU Clinical Trials Register and updated daily.

Ried Im Innkreis at a glance
123
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

123 trials in Ried Im Innkreis

Open in trial search

Crohn's disease

Recruiting

Study of JNJ-78934804 (guselkumab and golimumab) versus guselkumab in adults with moderately to severely active Crohn’s disease

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Golimumab
  • Sponsor:Janssen - Cilag International

Cardiac failure

Recruiting

Study of maridebart cafraglutide for patients with heart failure with preserved or mildly reduced ejection fraction and obesity

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Maridebart Cafraglutide
  • Sponsor:Amgen Inc.

Phase III Randomized Study of Balcinrenone and Dapagliflozin Versus Dapagliflozin on Renal and Cardiovascular Outcomes in Patients with Chronic Kidney Disease Stage 3b‑4

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Balcinrenone
  • Sponsor:Astrazeneca AB

A Phase III Study of Survodutide in Adults with Compensated NASH Cirrhosis to Assess Liver Outcomes and Safety

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Survodutide
  • Sponsor:Boehringer Ingelheim International GmbH

A Phase III trial of BI 456906 weekly injections in adults with NASH and stage 2‑3 liver fibrosis

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Survodutide
  • Sponsor:Boehringer Ingelheim International GmbH

Study of Zilebesiran Added to Standard Treatment to Reduce Heart Problems in Adults with High Blood Pressure and Heart Disease Risk

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Zilebesiran
  • Sponsor:Alnylam Pharmaceuticals Inc.

Study on Managing Heart Attack Risk with Icosapent Ethyl and Drug Combination for Patients at High Risk of Another Heart Attack

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Colchicine
  • Sponsor:Medical University Of Graz

Crohn's disease

Recruiting

Study on the Effectiveness and Safety of RO7790121 for Patients with Moderate to Severe Crohn's Disease

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:RO7790121
  • Sponsor:F. Hoffmann-La Roche AG

Study on the Effects of Pegozafermin for Patients with Nonalcoholic Steatohepatitis (NASH) and Fibrosis

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:BIO89-100
  • Sponsor:F. Hoffmann-La Roche AG

Cardiac failure

Recruiting

Study on the Effects of Finerenone in Patients with Heart Failure and Preserved Ejection Fraction Hospitalized for Acute Decompensated Heart Failure

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Finerenone
  • Sponsor:Colorado Prevention Center

Study of Camizestrant for Patients with ER+/HER2- Early Breast Cancer After 2 Years of Standard Endocrine Therapy

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:Astrazeneca AB

Efficacy and Safety of Oral PIPE-791 in Adults with Idiopathic Pulmonary Fibrosis: A Phase 2 Randomized, Double‑Blind, Placebo‑Controlled Study

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:PIPE-791
  • Sponsor:Contineum Therapeutics Inc.

Other cities in Austria

The busiest research cities in the country

All 48 cities in Austria

Clinical research in Ried Im Innkreis

What the registry says about research in the country

01 Breast Cancer Research

Innovative clinical trials focusing on hormone receptor-positive breast cancer treatment optimization. Research evaluates the effectiveness of combining endocrine therapy with new therapeutic approaches.

  • Early-stage breast cancer treatment
  • Hormone receptor-positive/HER2-negative cancer
  • Adjuvant therapy development

The studies aim to enhance treatment outcomes through combination therapy strategies, potentially improving disease-free survival rates for breast cancer patients.

02 Endocrine Therapy Studies

Research examining the optimization of standard adjuvant endocrine therapy protocols for breast cancer treatment, with a focus on combination approaches.

  • Long-term therapeutic strategies
  • Combination treatment protocols
  • Disease-free survival assessment

These trials explore innovative ways to enhance the effectiveness of established endocrine treatments through strategic therapeutic combinations.

03 Treatment Innovation

Groundbreaking research investigating targeted therapy combinations for specific breast cancer subtypes, focusing on improving patient outcomes.

  • Novel therapeutic combinations
  • Personalized treatment approaches
  • Long-term efficacy evaluation

Studies aim to establish more effective treatment protocols by combining established therapies with innovative approaches.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.